|Day Low/High||0.70 / 0.75|
|52 Wk Low/High||0.60 / 1.76|
After getting dinged by the U.S. trade deficit, the market should keep ticking along next week on quarterly reports.
The company's been oddly promotional throughout the Stellar 3 study, and this deal adds to the wonder.
Some notes and observations on Monday's activity at the UBS Global Life Sciences conference.
It's not surprising the stock is down since May, when the company dropped bullish hints about Xyotax.
The comany gets fast track approval status for its non-Hodgkin's lymphoma.
The HMO's execs have made out well with a rising stock, thanks in part to massive stock-option grants.
Response rates are high for its Xyotax in combination with platinates against tumors.
It's crucial to form your own definition of a significant stock move.
According to the chart, they'll halt their rise. Plus, Take-Two, Freddie Mac and more.
The question is what's behind Paramount's disbursement of 5.5 million shares to its investors.
Investors expecting a big European deal got a merger with a no-name company and a $100 million convertible.
The company will acquire Novuspharma for about $236 million in stock.
Its Xyotax is in phase II trials for non-small cell lung cancer.
The broader biotech sector measures are moving slightly lower.
No matter how much you think you know, it's better to trade what you see, rather than what you believe.
Investors had to look closely to discover the departure of two top executives.
Regulators seek information on how the American Society of Clinical Oncology releases research abstracts.
Soon-to-be-filed proxies and annual reports can reveal some startling corporate behavior.
Amgen appears to have a lot going for it. And Genzyme is starting to look like a turnaround.
The influential clinical oncology society tries to squelch the 'ASCO effect' by withholding abstracts until its meeting.
Midstage results show the company's reformulated version got good responses to four cancers.
Xyotax is not a sure thing, but some see high risk and high return in the reformulated cancer drug.
Amid signs the sector may finally have bottomed, here are some names that bear further watching.
Some of yesterday's gains are evaporating as the day goes on.
The Chartman offers his take on their use. Plus, charts of Disney, Boeing and more.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.